EBEmily C. Bartlett

Emily C. Bartlett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emily C. Bartlett has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Colour Doppler Ultrasonography in the Assessment of Intratesticular Lesions: Influence of Lesion Size and Vascular Pattern

    by Emily C. Bartlett, Dean Y. Huang, Marta Piorkowska, Maria E. Sellars, Jane L. Clarke, Seshadri Sriprasad, Gordon H. Muir, Daniel J. Quinlan, Paul S. Sidhu

    Background/Objectives: Conventional Colour Doppler Ultrasonography (CDUS) is widely used to assess vascularity in focal intratesticular lesions, yet the influence of lesion size on flow detection and the diagnostic utility of vascular distribution patterns remain unclear. We evaluated (i) whether lesion size affects CDUS detection of intralesional vascularity and (ii) whether vascular patterns associated with disruption of normal intratesticular vascular architecture are linked to diagnostic groupings. Methods: This retrospective single-centre study screened 12,189 testicular ultrasound examinations (1999–2009) and included histologically confirmed focal lesions with archived greyscale and CDUS images. To avoid within-patient clustering, one lesion per patient (the largest if multiple) was analysed (99 patients/lesions). Two blinded radiologists assessed vascularity (present/absent) and, for vascularised lesions, peripheral vascularity and intralesional patterns (criss-cross; disordered/haphazard). A derived composite “disrupted” pattern comprised criss-cross or disordered/haphazard flow. Results: Intralesional vascularity was present in 85/99 (85.9%) lesions. Vascularity was more common in neoplastic vs. non-neoplastic lesions (78/82 [95.1%] vs. 7/17 [58.8%]; p < 0.001) and in malignant vs. benign lesions (64/68 [94.1%] vs. 21/31 [67.7%]; p = 0.001). Lesion size was not associated with vascularity (the smallest vascularised lesion was 2 mm; logistic regression was non-significant). Among vascularised lesions, the composite disrupted pattern was more frequent in neoplastic vs. non-neoplastic (OR 11.67) and malignant vs. benign lesions (OR 5.90). Four of 14 avascular lesions were malignant/neoplastic. Conclusions: With optimised settings, CDUS vascularity detection did not appear size-limited and was strongly associated with neoplasia and malignancy, although avascularity did not exclude malignancy. A composite disrupted vascular pattern may be a practical, reproducible reporting descriptor warranting prospective validation.


  • Open Access

    Evaluation of the safety of short-term follow-up CT for the management of consolidation in lung cancer screening

    by Emily C. Bartlett, Ley Chan, Justin Garner, Sujal R. Desai, Samuel V. Kemp, Simon Padley, Bhavin Rawal, Carole A. Ridge, James Addis, Anand Devaraj

    Objectives: Focal consolidation on CT may be inflammatory or malignant, and PET-CT imaging is rarely discriminatory. Furthermore, consolidation may demonstrate spontaneous resolution obviating the need for PET-CT imaging. This retrospective study sought to assess the safety and cost-effectiveness of short-interval 6-week follow-up CT for consolidation in a lung cancer screening programme. Methods: Between January 2019 and January 2024, participants in a regional lung cancer screening programme with focal indeterminate consolidation underwent a 6-week repeat CT rather than immediate PET-CT and invasive investigation. The proportion of participants with non-resolving consolidation, the risk of malignancy in consolidation at a 6-week follow-up, and the risk of upstaging over a 6-week delay were determined. Cost savings were estimated from National Health Service reference costs. Results: In 10,247 CT studies, focal indeterminate consolidation was detected in 113 participants (1.1%) (mean age 68 years, range 55–76, 65 males). Consolidation spontaneously resolved at 6 weeks in 63/110 (57%) who attended follow-up; 14/110 (12.7%) participants had malignancy; no patients upstaged during follow-up. An estimated cost saving of £47,600/10,000 screening CTs performed might be obtained through a conservative approach of short-term interval CT, rather than immediate PET-CT and further investigation. Conclusion: Early repeat CT avoids PET-CT in more than half of patients with consolidation and can be utilised to reduce over-investigation of screen-detected consolidation, which may demonstrate spontaneous resolution. Key Points: Question Is short-term interval follow-up CT in lung cancer screening a safe and cost-effective approach to managing indeterminate (inflammatory or malignant) consolidation? Findings Short-interval CT imaging demonstrates spontaneous resolution of consolidation in over 50% participants in this study, whilst persistent consolidation has a high likelihood of malignancy. Clinical relevance Short-interval CT did not result in upstaging of malignancy and therefore can be considered a safe strategy to prevent the over-investigation of screen-detected consolidation, supporting recent European and American screening recommendations. Graphical

  • UK screening centre agreement on management of complex nodule management scenarios in lung screening

    by Emily Bartlett, Samuel Kemp, Mike Darby, James Shambrook, Arjun Nair, Hasti Robbie, Anand Devaraj

  • Open Access

    Defining growth in small pulmonary nodules using volumetry: results from a “coffee-break” CT study and implications for current nodule management guidelines

    by Emily C. Bartlett, Samuel V. Kemp, Bhavin Rawal, Anand Devaraj

    Objectives: An increase in lung nodule volume on serial CT may represent true growth or measurement variation. In nodule guidelines, a 25% increase in nodule volume is frequently used to determine that growth has occurred; this is based on previous same-day, test–retest (coffee-break) studies examining metastatic nodules. Whether results from prior studies apply to small non-metastatic nodules is unknown. This study aimed to establish the interscan variability in the volumetric measurements of small-sized non-metastatic nodules. Methods: Institutional review board approval was obtained for this study. Between March 2019 and January 2021, 45 adults (25 males; mean age 65 years, range 37–84 years) with previously identified pulmonary nodules (30–150 mm3) requiring surveillance, without a known primary tumour, underwent two same-day CT scans. Non-calcified solid nodules were measured using commercial volumetry software, and interscan variability of volume measurements was assessed using a Bland–Altman method and limits of agreement. Results: One hundred nodules (range 28–170 mm3; mean 81.1 mm3) were analysed. The lower and upper limits of agreement for the absolute volume difference between the two scans were − 14.2 mm3 and 12.0 mm3 respectively (mean difference 1.09 mm3, range − 33–12 mm3). The lower and upper limits of agreement for relative volume difference were − 16.4% and 14.6% respectively (mean difference 0.90%, range − 24.1–32.8%). Conclusions: The interscan volume variability in this cohort of small non-metastatic nodules was smaller than that in previous studies involving lung metastases of varying sizes. An increase of 15% in nodule volume on sequential CT may represent true growth, and closer surveillance of these nodules may be warranted. Key Points: • In current pulmonary nodule management guidelines, a threshold of 25% increase in volume is required to determine that true growth of a pulmonary nodule has occurred. • This test–retest (coffee break) study has demonstrated that a smaller threshold of 15% increase in volume may represent true growth in small non-metastatic nodules. • Closer surveillance of some small nodules growing 15–25% over a short interval may be appropriate.


  • Open Access

    Implications of incidental findings from lung screening for primary care: data from a UK pilot

    by Emily C. Bartlett, Jonathan Belsey, Jane Derbyshire, Katie Morris, Michelle Chen, James Addis, Maria Martins, Carole A. Ridge, Sujal R. Desai, Saeed Mirsadraee, et al.

    Regional lung cancer screening (LCS) is underway in England, involving a “lung health check” (LHC) and low-dose CT scan for those at high risk of cancer. Incidental findings from LHCs or CTs are usually referred to primary care. We describe the proportion of participants referred from the West London LCS pilot to primary care, the indications for referral, the number of general practitioner (GP) attendances and consequent changes to patient management, and provide an estimated cost-burden analysis for primary care. A small proportion (163/1542, 10.6%) of LHC attendees were referred to primary care, primarily for suspected undiagnosed chronic obstructive pulmonary disease (55/163, 33.7%) or for QRISK® (63/163, 38.7%) assessment. Ninety one of 159 (57.2%) participants consenting to follow-up attended GP appointments; costs incurred by primary care were estimated at £5.69/LHC participant. Patient management changes occurred in only 36/159 (22.6%) referred participants. LHCs result in a small increase to primary care workload provided a strict referral protocol is adhered to. Changes to patient management arising from incidental findings referrals are infrequent.


  • Baseline Results of the West London lung cancer screening pilot study – Impact of mobile scanners and dual risk model utilisation

    by Emily C. Bartlett, Samuel V. Kemp, Carole A. Ridge, Sujal R. Desai, Saeed Mirsadraee, Jaymin B. Morjaria, Pallav L. Shah, Sanjay Popat, Andrew G. Nicholson, Alexandra J. Rice, et al.


  • MA10.10 Uptake in Lung Cancer Screening – Does CT Location Matter? A Pilot Study Comparison of a Mobile and Hospital Based CT Scanner

    by E. Bartlett, S. Kemp, S. Desai, S. Mirsadraee, C. Ridge, J. Morjaria, P. Shah, K. Morris, J. Derbyshire, M. Chen, et al.